Phase 3 PROSTATE-IQ Trial Launches to Reduce Hormone Therapy Burden in Prostate Cancer Patients
• The phase 3 PROSTATE-IQ trial has enrolled its first patient, evaluating ArteraAI Prostate Test's ability to identify men who can safely reduce or avoid hormone therapy after prostatectomy.
• The study will stratify patients with biochemical recurrence into risk groups, with low-risk patients receiving either 6 months of ADT or apalutamide monotherapy, while high-risk patients receive either 24 months of ADT or 6 months of ADT with apalutamide.
• Led by Dr. Karen Elizabeth Hoffman from MD Anderson Cancer Center, the trial aims to improve quality of life by minimizing hormone therapy side effects while maintaining treatment efficacy across 11 clinical sites in the US.
© Copyright 2025. All Rights Reserved by MedPath